Layerly Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 19-12-2024
- Paid Up Capital ₹ 0.20 M
as on 19-12-2024
- Company Age 5 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Revenue -51.40%
(FY 2022)
- Profit 13.54%
(FY 2022)
- Ebitda 8.51%
(FY 2022)
- Net Worth -54.41%
(FY 2022)
- Total Assets 67.82%
(FY 2022)
About Layerly Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Udaya Perla and Srinivasa Yadala serve as directors at the Company.
- CIN/LLPIN
U24110TG2019PTC133555
- Company No.
133555
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jun 2019
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Layerly Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Udaya Perla  | Managing Director | 20-Jun-2019 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Srinivasa Yadala | Director | 20-Jun-2019 | Current |
Financial Performance of Layerly Pharmaceuticals.
Layerly Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 51.4% decrease. The company also saw a substantial improvement in profitability, with a 13.54% increase in profit. The company's net worth observed a substantial decline by a decrease of 54.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Layerly Pharmaceuticals?
In 2022, Layerly Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Sarath Meditech Private LimitedActive 2 years 3 months
Udaya Perla and Srinivasa Yadala are mutual person
- Starus Pharmaceuticals Industries Private LimitedActive 5 years 1 month
Udaya Perla is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Layerly Pharmaceuticals?
Layerly Pharmaceuticals has a workforce of 2 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Layerly Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Layerly Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
